Board of Directors

Dr Taylor joined Clarity’s Board in November 2013 as Executive Chairperson. He has been instrumental in the growth of Clarity and has been heavily involved in all areas of the Company’s business.

Dr Taylor has over 15 years of investment banking experience focused predominantly on the life sciences sector, and has significant expertise in capital raisings, mergers and acquisitions, and general corporate advisory. Prior to joining Clarity, he was an Executive Director of Inteq Limited, a boutique Australian investment bank.

After receiving the University Medal for his undergraduate degree in Applied Science at the University of Sydney, Dr Taylor completed his PhD in Medicine at the Garvan Institute of Medical Research. He has also completed a Graduate Diploma in Applied Finance at the Securities Institute of Australia.

Ms Parker is a long-time member of Clarity’s senior executive team, having joined the Company in June 2018 and now serving as Chief Executive Officer and Managing Director. She has led Clarity’s rapidly advancing clinical strategy and has been instrumental in advancing three key products from preclinical and early-stage clinical studies to late-stage and registrational Phase III trials.

Ms Parker has over 20 years of experience spanning nuclear medicine, positron emission tomography and pharmaceuticals in Australia and internationally.  Prior to joining Clarity, Ms Parker held the position of Head of International Clinical Research Operations at Novartis Australia, a global pharmaceutical company, where she led a multi-disciplinary, high performing team of over 35 associates responsible for end-to-end clinical trial execution.

Ms Parker holds a Bachelor of Applied Science in Medical Radiation Technology (Nuclear Medicine) from the University of Sydney.

Ms Robinson joined Clarity’s Board in October 2010 as a Non-Executive Director. She brings extensive experience in the nuclear field and a range of commercial and operational expertise to the Company. Ms Robinson has over 25 years of experience in senior leadership and governance roles in public and private companies, as well as government. Ms Robinson is currently the Chief Operating Officer of Cyclotek (Aust) Pty Ltd and has been previously working for over 13 years at the Australian Nuclear Science and Technology Organisation (ANSTO) as a General Manager, Business Development. Her in-depth knowledge of the nuclear medicine industry is highly valued at Clarity as Ms Robinson provides a clear vision across the dynamics of a rapidly evolving segment of the healthcare industry.

Ms Robinson holds a Bachelor of Business (Accounting), a Graduate Diploma of Accounting (CA) and is a Graduate of the Australian Institute of Company Directors.

Dr Roberts joined Clarity’s Board in March 2016 as a Non-Executive Director. He has over 40 years of experience in the medical innovation space and has served on the boards of a number of ASX-listed companies during his career. He was previously the CEO of Cochlear Limited, and Chairman of Sirtex Medical Ltd. Dr Roberts was also Executive Vice-President and Director of the dual-listed (ASX and NYSE) company ResMed Inc. He is a Non-Executive Director of ASX-listed HealthCo Health and Wellness REIT, Atmo Biosciences Limited, Sigma Healthcare Ltd, and O’Connell Street Associates Pty Ltd, and is a Non-Executive Director and Chairman of Nutromics Pty Limited, Director of HMC Capital Partners Fund 1, and Governor for the Centenary Institute of Cancer Medicine and Cell Biology.

Dr Roberts holds a Bachelor of Engineering (Honours) in Chemical Engineering from the University of New South Wales, an MBA from Macquarie University and a PhD from the University of New South Wales. He has also been awarded Honorary Doctor of Science degrees from Macquarie University and the University of New South Wales.

Dr Ramdahl joined Clarity’s Board in March 2019 as a Non-Executive Director. He is a pharmaceutical executive with over 20 years of clinical and development experience. In 2001, he became President and the first CEO of Algeta ASA. When Dr Ramdahl joined Algeta, he was one of six employees and he played an instrumental role in its success, including the approval of the alpha particle emitting radiopharmaceutical Xofigo®, serving in several senior positions within the company through to and post the acquisition of Algeta by Bayer AG in 2014 for US$2.9 billion. Dr Ramdahl has authored more than 40 publications and is a co-inventor of several patents. He currently serves as a Director of Precirix (Belgium), Chairman of Agiana Pharmaceuticals (Norway), and Director of companies related to multiple HealthCap entities.

Dr Ramdahl gained his PhD in Environmental Chemistry from the University of Oslo and holds a Master of Science in Organic Chemistry from the Norwegian Institute of Technology.

Dr Biggin joined Clarity’s Board in October 2019 after playing an instrumental role in enhancing and designing the Company’s product development and clinical programmes since he first joined the Company in January 2017. He is now serving as Clarity’s Chief Operating Officer.

Dr Biggin has over 15 years of radiopharmaceutical development and commercialisation experience. Dr Biggin previously served with Algeta ASA during the development and commercialisation of its product Xofigo® (radium-223 dichloride) for metastatic prostate cancer, which was approved by the FDA in 2013. Prior to joining the Company, Dr Biggin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.

Dr Biggin holds a Bachelor of Science (Honours) and a PhD from the University of Glasgow.